Veille MPox

Des médecins américains rapportent le cas d’un homme de 34 ans qui a contracté le monkeypox (variole du singe) bien que vacciné contre la variole huit ans auparavant. Il avait reçu le vaccin ACAM2000, vaccin antivariolique vivant atténué de « deuxième génération » produit sur culture cellulaire. Celui-ci contient le virus de la vaccine, virus …

Continuer la lecture de « Quand un vaccin contre la variole ne protège pas du monkeypox »

Nature Medicine explores the latest translational and clinical research news

This guidance describes FDA’s review priorities and enforcement policies for monkeypox tests to address the public health emergency.

The current monkeypox virus global spread and lack of data regarding clinical specimens’ infectivity call for examining virus infectivity, and whether this correlates with results from PCR, the available diagnostic tool. We show strong correlation between viral DNA amount in clinical specimens and virus infectivity toward BSC-1 cell line. Moreover, we define a PCR threshold value (Cq ≥ 35, ≤ 4,300 DNA copies/mL), corresponding to negative viral cultures, which may assist risk-assessment and decision-making regarding protective-measures and guidelines for patients with monkeypox.

Intradermal Vaccination for Monkeypox Intradermal JYNNEOS may safely provide populations that have been disproportionately affected by monkeypox with rapid access to a limited resource withou

Tecovirimat, a little-known antiviral, shows promise against monkeypox. But human data and supplies of the drug are limited.

This case series describes the clinical resolution of systemic symptoms and lesions, along with any adverse events, in patients with monkeypox infection who were treated with tecovirimat on a compassionate use basis.

Introduction A multicountry monkeypox disease (MPX) outbreak began in May 2022 in Europe, leading to the assessment as a potential Public Health Emergency of International Concern (PHEIC) on June 23, 2022. Some observational studies have partially characterised clinical features, hospitalisations, and deaths. However, no systematic reviews of this MPX outbreak have been published. Methods We performed a systematic review with meta-analysis, using five databases to assess clinical features, hospitalisations, complications and deaths of MPX confirmed or probable cases. Observational studies, case reports and case series, were included. We performed a random-effects model meta-analysis to calculate the pooled prevalence and 95% confidence interval (95% CI). In addition, we carried out a subgroup analysis according to the continents and a sensitivity analysis excluding studies classified as having a high risk of bias. Results A total of 19 articles were included, using only 12 articles in the quantitative synthesis (meta-analysis). For 1958 patients, rash (93%, 95% CI 80–100%), fever (72%, 95% CI 30–99%), pruritus (65%, 95% CI 47–81%), and lymphadenopathy (62%, 47–76%), were the most prevalent manifestations. Among the patients, 35% (95% CI 14–59%) were hospitalised. Some 4% (95% CI 1–9%) of hospitalised patients had fatal outcomes (case fatality rate, CFR). Conclusion MPX is spreading rapidly, with a third of hospitalised patients, but less than 5% with fatal outcomes. As this zoonotic virus spreads globally, countries must urgently prepare human resources, infrastructure and facilities to treat patients according to the emerging guidelines and the most reliable clinical information.

This document provides guidance on infection prevention and control (IPC) measures for primary and acute healthcare settings in the European Union/European Economic Area (EU/EEA) to prevent healthcare-associated transmission of monkeypox (MPX).

Symptoms of severe disease differ from those seen during past outbreaks, causing researchers to re-evaluate their assumptions.

Monkeypox Emergency Use Authorizations for Medical Devices

This Medical News article discusses recent European reports of asymptomatic monkeypox virus infections.

In the current monkeypox outbreak, vaccination and treatment of pregnant women are recommended only if the benefits outweigh risks, but the extremely sparse data available limit evidence-based recommendations. We must facilitate a unified consensus approach to rapidly collect robust data. Two years into the COVID-19 pandemic, monkeypox has emerged as yet another challenge to the mother-fetus dyad, potentially placing both at risk, if exposed.

Tecovirimat and the Treatment of Monkeypox Tecovirimat might speed resolution of monkeypox illness and improve outcomes, but how can we manage compassionate access to a drug whose safety an